氯诺昔康治疗中重度癌痛32例

INTRODUCTION２０００－０２／０８，effectoflornoxicam（LNS）oncancerpainwastestedclinicallyinTumorHospital，ChineseAcademyofMedicalScience，PekingUnionMedicalCollege．ThetestwasratifiedbyStateDrugadministrationandinchargeofTumorHospital，ChineseAcademyofMedicalScience，PekingUnionMedicalCollege．Theobjectiveoftestwastoinvestigateadministrationapproaches，efficacy，andsafetyofLNXoncancerpain[１－５]．SUBJECTSANDMETHODSSubjects３２patientswereevaluatedincluding１８menand１…

Treatment of moderate and severe cancerpain by Lornoxicam: 32 cases report

AIM: To study efficacy, safety, administration approaches of pellet of lornoxicam in treating pain caused by moderate and advanced cancers(import clinical verification) . METHOS: Multiple center, random, double blind, and sele-control method was used. Lornoxicam and positive control drug (tramadol) was randomly labeled as A and B. All qualified patients accepted A and B in turn. Purge drugs was given during interval. Number evaluation method was used to assay pain level and changes. Effective period, optimal relief time, and duration were computed. Level of adverse effects and its relation with drugs were evaluated. RESULTS: 32 patients were evaluated including 22 cases of moderate pain and 10 of advanced pain. When approaches of drug administered were stratified, there was no significant difference in efficacy between A and B considering single drug titration for drug administration according to need or time. Administration approaches included 2 pellets a time, twice a day(2#B1D); 1 pellet a time, three times a day(1#TID); 1 pellet a time, twice a day(1#BID) . When stratification was carried out according to pain severity, efficacy of A and B for moderate pain and severe pain variet between 74.2% - 92.3% , 55.0% - 92. 6% , respectively. There was no significant difference. Work time, optimal relief time, and duration for A and B were about 0. 8 hour, 1.5 hour, and 8. 2 hour. There was no statistical significance. Incidence of adverse effect for lornoxicam and tramadol was 20. 0% and 33.3% ,respectively( P ＜ 0. 05). Superiority score for them was 7.6 :± 2.4 and 6. 1 ± 2. 1, respectivley( P ＜ 0.05 ) . CONCLUSION: Lomoxicam had favorable effect on moderate and severe cancer pain, and is similar to drug of second rung such as tramadol. But its adverse reactions are slighter and less common compared with tramadol. Patients' content degree for lornoxicam is higher than that for tramsdol. 2#BID, 1#TID, 1#BID are more common. Considering small sample, its efficacy, therapeutic effect, safety need further investigation.